In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008–16 | Zendy

Andrew Walkty | Zendy; Heather J. Adam | Zendy; Melanie Baxter | Zendy; Philippe LagacéWiens | Zendy; James A. Karlowsky | Zendy; Daryl J. Hoban | Zendy; George G. Zhanel | Zendy

Open Access

In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008–16

Author(s) -

Andrew Walkty,

Heather J. Adam,

Melanie Baxter,

Philippe LagacéWiens,

James A. Karlowsky,

Daryl J. Hoban,

George G. Zhanel

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx468

Subject(s) - pseudomonas aeruginosa , antimicrobial , microbiology and biotechnology , tazobactam , broth microdilution , ciprofloxacin , amikacin , biology , antibiotics , medicine , antibiotic resistance , minimum inhibitory concentration , bacteria , imipenem , genetics

Ceftolozane/tazobactam is a novel β-lactam β-lactamase inhibitor combination with a broad spectrum of activity that includes Pseudomonas aeruginosa. The purpose of this study was to evaluate the in vitro activity of ceftolozane/tazobactam and relevant comparators versus a large collection of antimicrobial non-susceptible P. aeruginosa clinical isolates recovered from patients across Canada (CANWARD, 2008-16).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research